Study Title

curium

Phase 3 Trial of 177Lu-PSMA I&T versus Hormone Therapy in Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study Details

Description:

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Sponsor:

Curium

Contacts:

Darcy Denner, Ph.D. (Clinical Trial Director)

darcy.denner@curiumpharma.com

Inclusion
  • Males, 18 years or older
  • Positive PSMA PET scan
  • Proven metastatic castration-resistant prostate cancer
Exclusion
  • Previous treatment with chemotherapy in the castration-resistant setting
  • Previous treatment with more than one ARAT
  • Previous treatment with other radioligand therapy

Publications

Publications Not Yet Provided

Locations

United States


































© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468